Abstract: The present invention relates to the field of bio-pharmaceuticals and provides an anti-CLDN18.2 antibody. Related preparation methods and related uses are described. The antibody of the present invention or related an antigen-binding fragment can specifically bind to CLDN18.2 with a strong binding capacity. After humanization, the antibody or the antigen-binding fragment has a strong ADCC effect and CDC activity and has good pharmaceutical prospects.

Abstract: The present invention provides a bispecific antibody and use thereof, and the bispecific antibody or an antigen-binding fragment of the present invention can bind to two or more antigens or two or more epitopes of a same antigen. The antibody or the antigen-binding fragment of the present invention can be used to treat a variety of diseases, such as inflammatory diseases, autoimmune diseases, cancers or spinal cord injury, and can also be used for diagnosis and prognosis of related diseases.

Abstract: Disclosed are anti-PD-1 antibodies and use of an anti-PD-1 antibody in a combination therapy. Treatment methods are disclosed and include administering to a patient in need an effective amount of an anti-PD-1 antibody and a therapeutic agent. Methods for treating a tumor or cancer using anti-PD-1 antibody and a therapeutic agent are disclosed.

Abstract: The use of an anti-OX40 antibody or an antigen-binding fragment in the treatment of a tumor or cancer, is described. Also described is a treatment method of a tumor or cancer and includes administering to a patient in need an effective amount of an anti-OX40 antibody or an antigen-binding fragment. Kits including an anti-OX40 antibody or an antigen-binding fragment are also described.

Abstract: Disclosed are anti-CD20 antibody formulations and use of anti-CD20 antibodies for the treatment of CD20 positive diseases, such as methods of using anti-CD20 antibodies for treating CD20 positive diseases, such as neuromyelitis optica spectrum disorders (NMOSD), non-Hodgkin's lymphoma (NHL), multiple sclerosis (MS), immune thrombocytopenia (ITP), rheumatoid arthritis (RA), Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), lupus nephritis, systemic lupus erythematosus and chronic lymphocytic leukemia (CLL).

Abstract: A lens plate has an array of lenslets. A first surface comprises a plurality of individual cells, each cell delimiting one side of a respective lenslet of the array. A second opposite surface comprises a set of grooves, each groove delimiting a second, opposite side, of a sub-array of the lenslets of the array of lenslets. The array of lenslets is a circular array comprising a plurality of concentric rings. Each ring comprises a plurality of straight segments, and each segment comprises multiple said lenslets arranged in a row. The lens plate design thus combines grooves on one side which cover multiple lenslets and a cellular lens structure on the opposite side.

Abstract: CD47 antibodies and use thereof are disclosed, particularly to monoclonal antibodies that recognize CD47, and more particularly to CD47 antibodies that do not cause significant levels of hemagglutination, red blood cell reduction and platelet reduction, and to a method for preparing these antibodies and use of these monoclonal antibodies in the manufacture of medicaments for treating cancer or infection.

Abstract: Disclosed are anti-PD-L1 antibodies and use of anti-PD-1 antibodies. The antibody or the antigen-binding fragment can specifically bind to PD-L1 and block the interaction between PD-1 and PD-L1. The antibody or the antigen-binding fragment can help the immune system to clear tumor cells, and can also be used for the diagnosis and prognosis of a tumor or a cancer.

Abstract: Disclosed is an anti-CTLA-4 monoclonal antibody and a preparation and use thereof. The anti-CTLA-4 antibody has the advantages of lower toxicity and better activity; in addition, the anti-CTLA-4 antibody also has a low content of high mannose glycoforms and/or a low content of sialylated glycoforms, which helps to prolong the half-life of the antibody and/or reduce immunogenicity. In addition, disclosed is a formulation with the antibody which has good stability.

Abstract: The invention relates to a liquid formulation of humanized antibody for treating IL-6 related diseases. The liquid formulation contains 2-100 mg/ml recombinant humanized anti-human interleukin 6 receptor monoclonal antibody, 5-20 mM histidine salt buffer (or a buffer of a combination of 5-20 mM histidine salt and 5-20 mM sodium acetate), 0.025-0.075% (by volume) surfactant, and 3-5% (by mass to volume) stabilizer and water for injection. The antibody formulation enhances the stability of the recombinant anti-human interleukin 6 receptor monoclonal antibody, prevents the monoclonal antibody from aggregation, degradation, and acidic isomer increases. This formulation can be used for stabilizing the structure and function of the humanized antibody.

Abstract: An anti-TNF-? antibody formulation, and a preparation method and use of the anti-TNF-? antibody is disclosed. The anti-TNF-? antibody formulation, preparation method, and use relates to the field of pharmacy. The formulation includes an anti-TNF-? antibody and a pharmaceutically acceptable carrier. The anti-TNF-? antibody includes a heavy chain with an amino acid sequence set forth in SEQ ID NO: 1 and a light chain with an amino acid sequence set forth in SEQ ID NO: 2. The pharmaceutically acceptable carrier includes a stabilizer, a surfactant and a buffer. The disclosed antibody formulation has high stability and does not support microorganism growth.

Abstract: The development and use of an anti-OX40 antibody and immune cell activation is disclosed. The anti-OX40 antibody or a fragment of the anti-OX40 antibody retains strong binding to human OX40 or Rhesus Monkey OX40. The anti-OX40 antibody or a fragment of the anti-OX40 antibody more effectively activates T cells, generates stronger immune responses, and improves anti-tumor activity.

Abstract: A power converter includes: a switching transistor, a transformer, a control circuit; the control circuit is configured to determine a target voltage in a process that the switching transistor is driven to conduct; the target voltage can represent a voltage change of an input terminal of the switching transistor; when the target voltage starts to drop but is higher than a reference voltage, drive a control terminal of the switching transistor with a first driving current; when the target voltage decreases to be lower than the reference voltage, drive the switching transistor with a second driving current; the second driving current is higher than the first driving current; the switching transistor is driven by the first driving current for part or all of the time before entering the Miller plateau stage, and is driven by the second driving current after starting to enter the Miller plateau stage.

Abstract: A power converter includes: a switching transistor, a transformer, a control circuit; the control circuit is configured to determine a target voltage in a process that the switching transistor is driven to conduct; the target voltage can represent a voltage change of an input terminal of the switching transistor; when the target voltage starts to drop but is higher than a reference voltage, drive a control terminal of the switching transistor with a first driving current; when the target voltage decreases to be lower than the reference voltage, drive the switching transistor with a second driving current; the second driving current is higher than the first driving current; the switching transistor is driven by the first driving current for part or all of the time before entering the Miller plateau stage, and is driven by the second driving current after starting to enter the Miller plateau stage.

Abstract: The present invention provides an anti-TIGIT immunosuppressant and use thereof. The immunosuppressant can bind to the extracellular region of human TIGIT, and can be used for treating diseases such as a cancer.

Abstract: Disclosed herein are antibodies that bind to PD-1, comprising one or more CDRs selected from the amino acid sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18. The antibodies have high affinity and low dissociation rate for PD-1, as well as the activity for neutralizing PD-1 in vitro. The antibodies disclosed herein can be full-length antibodies or antigen-binding fragments thereof. The antibodies can be used for detecting PD-1 and the like.

Abstract: The invention relates to a liquid formulation of humanized antibody for treating IL-6 related diseases. The liquid formulation contains 2-100 mg/ml recombinant humanized anti-human interleukin 6 receptor monoclonal antibody, 5-20 mM histidine salt buffer (or a buffer of a combination of 5-20 mM histidine salt and 5-20 mM sodium acetate), 0.025-0.075% (by volume) surfactant, and 3-5% (by mass to volume) stabilizer and water for injection. The antibody formulation enhances the stability of the recombinant anti-human interleukin 6 receptor monoclonal antibody, prevents the monoclonal antibody from aggregation, degradation, and acidic isomer increases. This formulation can be used for stabilizing the structure and function of the humanized antibody.

Abstract: Provided is a conversion process for an organic oil, relating to the field of biomass utilization, energy and chemical industry. The conversion process is carried out in presence of an aqueous slurry and a catalyst selected from the group consisting of an iron oxide compound, a waste agent resulting from use of an iron oxide compound as desulfurizer, and a regeneration product of the waste agent, under a controlled molar ratio of iron element to sulfur element. It is found that free radical condensation polymerization of organic oil during cracking process can be blocked effectively by using carbonylation, and hydrogenation is achieved with active hydrogen produced from the conversion of CO and water. In the conversion process, organic material, especially biomass solid, can be directly converted without dehydration, and water can be additionally added to the biomass liquid or the mineral oil.

Abstract: The present invention generally relates to compounds comprising antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to TROP2 (TACSTD2). The present invention also relates to methods of using such TROP2-binding molecules for diagnosing and treating diseases, such as malignancies.

Abstract: The present disclosure discloses a data information processing method. A storage space corresponding to an organization is disposed in a data storage system. A data processing request type, the storage partition in which a project sending a data processing request is located, and the storage partition of the target data information corresponding to the data processing request are acquired when the data processing request is received. Subsequently, a processing strategy matching the storage partitions and the type is acquired. Finally, the target data information is processed according to the processing strategy and the data processing request. Thus, the isolation and rights control of different data in the same storage space can be achieved, and the security and mobility of data can be ensured.